CHAPEL HILL — Two professors from UNC-Chapel Hill’s School of Medicine filed an application with the U.S. Patent and Trademark Office for new approaches to treating heart failure.
Monte Willis, professor in the Department of Pathology and Laboratory Medicine, and Scott Bultman, associate professor in the Department of Genetics, filed the patent application.
The Patent and Trademark Office made the filing public Thursday.
According to the application, “the present invention relates to methods and compositions for treating heart failure in a subject using histone deacetylase (HDAC) inhibitors and/or histone acetyltransferases (HAT) activators.”
The claims made for methods of treatment in the application include increasing and decreasing the function of different proteins in patients.
A statement of federal support for the invention, awarded by the National Institutes of Health, was included in the application.
“The government has certain rights in the invention,” the application stated.
This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism
